<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND: <z:mpath ids='MPATH_124'>Infarct</z:mpath> size predicts post-infarction mortality </plain></SENT>
<SENT sid="1" pm="."><plain>Oral β-blockade within 24 hours of a ST-segment elevation <z:hpo ids='HP_0011009'>acute</z:hpo> <z:hpo ids='HP_0001658'>myocardial infarction</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">STEMI</z:e>) is a class-IA indication, however early intravenous (IV) β-blockers initiation is not encouraged </plain></SENT>
<SENT sid="2" pm="."><plain>In recent magnetic resonance imaging (MRI)-based experimental studies, the β(1)-blocker <z:chebi fb="0" ids="6904">metoprolol</z:chebi> has been shown to reduce <z:mpath ids='MPATH_124'>infarct</z:mpath> size only when administered before coronary reperfusion </plain></SENT>
<SENT sid="3" pm="."><plain>To date, there is not a single trial comparing the pre- vs. post-reperfusion β-blocker initiation in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">STEMI</z:e> </plain></SENT>
<SENT sid="4" pm="."><plain>OBJECTIVE: The METOCARD-CNIC trial is testing whether the early initiation of IV <z:chebi fb="0" ids="6904">metoprolol</z:chebi> before primary percutaneous coronary intervention (pPCI) could reduce <z:mpath ids='MPATH_124'>infarct</z:mpath> size and improve outcomes when compared to oral post-pPCI <z:chebi fb="0" ids="6904">metoprolol</z:chebi> initiation </plain></SENT>
<SENT sid="5" pm="."><plain>DESIGN: The METOCARD-CNIC trial is a randomized parallel-group single-blind (to outcome evaluators) clinical effectiveness trial conducted in 5 Counties across Spain that will enroll 220 participants </plain></SENT>
<SENT sid="6" pm="."><plain>Eligible are 18- to 80-year-old patients with anterior <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">STEMI</z:e> revascularized by pPCI ≤6 hours from symptom <z:hpo ids='HP_0003674'>onset</z:hpo> </plain></SENT>
<SENT sid="7" pm="."><plain>Exclusion criteria are Killip-class ≥III, <z:hpo ids='HP_0001678'>atrioventricular block</z:hpo> or active treatment with β-blockers/<z:chebi fb="1" ids="35523">bronchodilators</z:chebi> </plain></SENT>
<SENT sid="8" pm="."><plain>Primary end point is <z:mpath ids='MPATH_124'>infarct</z:mpath> size evaluated by MRI 5 to 7 days post-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">STEMI</z:e> </plain></SENT>
<SENT sid="9" pm="."><plain>Prespecified major secondary end points are salvage-index, left ventricular ejection fraction recovery (day 5-7 to 6 months), the composite of (<z:hpo ids='HP_0011420'>death</z:hpo>/malignant <z:hpo ids='HP_0004308'>ventricular arrhythmias</z:hpo>/reinfarction/admission due to <z:hpo ids='HP_0001635'>heart failure</z:hpo>), and myocardial perfusion </plain></SENT>
<SENT sid="10" pm="."><plain>CONCLUSIONS: The METOCARD-CNIC trial is testing the hypothesis that the early initiation of IV <z:chebi fb="0" ids="6904">metoprolol</z:chebi> pre-reperfusion reduces <z:mpath ids='MPATH_124'>infarct</z:mpath> size in comparison to initiation of oral <z:chebi fb="0" ids="6904">metoprolol</z:chebi> post-reperfusion </plain></SENT>
<SENT sid="11" pm="."><plain>Given the implications of <z:mpath ids='MPATH_124'>infarct</z:mpath> size reduction in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">STEMI</z:e>, if positive, this trial might evidence that a refined use of an approved inexpensive drug can improve outcomes of patients with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">STEMI</z:e> </plain></SENT>
</text></document>